Get startedLog in
    Picture of Damora Therapeutics logo

    DMRA — Damora Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapMomentum Trap
    All News

    Brief: Galecto Completes Dosing In 52-Week Phase 2b GALACTIC-1 Trial Of GB0139 In Idiopathic Pulmonary Fibrosis

    Picture of Damora Therapeutics logoDamora Therapeutics
    23/05/2023 14:23
    May 23 (Reuters) - Galecto Inc  GLTO.O :
    * GALECTO COMPLETES DOSING IN 52-WEEK PHASE 2B GALACTIC-1
TRIAL OF
GB0139 IN IDIOPATHIC PULMONARY FIBROSIS

Source text for Eikon:  ID:nGNXhHRDG 
Further company coverage:  GLTO.O 

 ((reuters.briefs@thomsonreuters.com;))

    Recent news on Damora Therapeutics

    See all news